Adapting a communication program for Latinx cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to translate and tailor a program called Communicating with Oncology Nurses about Values from the Outset (CONVO) specifically for Latinx participants. The program involves discussions between oncology nurses and patients about their health-related values as part of routine cancer care. The focus is on Spanish-speaking adults with solid tumors receiving medical oncology care at specific locations in the Bronx, New York. The study seeks to enhance communication and understanding of patient values in cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All participants will be adults (age ≥ 21) providing informed verbal consent. We seek a waiver of signed consent, which will allow use of virtual communication during the COVID-19 pandemic period.
* Patients will be eligible as key informants in the translation/transcreation process (Aim 1) if they are receiving medical oncology care for a solid tumor malignancy at RLC, SBH, or Jacobi and speak Spanish as their preferred language. In addition, English-speaking Latinx patients will be eligible to participate in interviews based on the back-translated (Spanish-to-English) version of the Guide

  * We are focusing on patients with solid tumors rather than hematologic malignancies because 1) patients in the latter group may be receiving initial oncologic treatment in the hospital, whereas our study staff will be based at a distance from the hospital in the ambulatory clinics; 2) the trajectory, patient characteristics, and other aspects of hematologic malignancies tend to be different from solid tumor malignancies such that it would be more difficult to understand the overall impact of the intervention if patients with both types of malignancies w ere included.
* Spanish-speaking family/other informal caregivers (collectively referred to as "family") who accompany participating patients to clinic will also be eligible to participate in interviews as part of the Aim 1 translation/transcreation process. These will be individual interviews, conducted separately for patient and family participants.
* Clinicians eligible for participation in the transcreation will be oncology physicians, nurses and other key clinical staff (e.g. social workers, advance practice providers, etc.) at RLC and other MSK sites who are Latinx and/or whose practice includes \>20% Latinx patients.
* Site leaders at SBH, Jacobi, and RLC with administrative responsibility for medical oncology will be eligible as key informants in transcreation of CONVO.
* For the Aim 2 pilot trial, patients will be eligible if they are receiving systemic chemotherapy at SBH or Jacobi for a solid tumor; identify as Latinx; and speak English and/or Spanish. Family and/or informal caregivers who accompany the patient and speak English and/or Spanish will also be eligible (if the patient opts to include the family and/or informal caregiver in the CONVO discussion).
* Nurses providing outpatient oncology care in chemotherapy areas at SBH or Jacobi will be eligible to participate in the pilot trial.

Exclusion Criteria:

* Inability to understand consent procedure in either English or Spanish will be an exclusion. (The consenting professional will be bilingual \[English/Spanish\] and able to explain and obtain consent in either language.)

Where it's running

• MSK at Ralph Lauren (All Protocol Activities)
  New York, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting
• SBH Health System
  The Bronx, New York, United States Recruiting
• Jacobi Medical Center
  The Bronx, New York, United States Recruiting
• New York Cancer & Blood Specialists (Data collection only)
  The Bronx, New York, United States Recruiting

Study contacts

• Principal investigator: Judith Nelson, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Judith Nelson, MD
• Email: nelsonj@mskcc.org
• Phone: 646-888-3107

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating AD1208 for advanced solid tumors

  This study is testing a new drug called AD1208 to see if it is safe and tolerable for people with advanced solid tumors.

  Recruiting at 3 sites Phase 1/2 Avelos Therapeutics Inc. · Seongnam-si, Gyeonggi-do and 2 other locations · NCT06911333

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• R-5780 with PD-1 blockers for adults with advanced melanoma and other solid tumors

  This Phase 1 test will try an oral probiotic called R-5780 together with PD-1 checkpoint inhibitors to see if adults with advanced solid tumors can tolerate it safely.

  Recruiting at 2 sites Phase 1 Rise Therapeutics LLC · Denver, Colorado and 1 other locations · NCT06398418

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• INV-1120 alone and with pembrolizumab for adults with advanced solid tumors

  This Phase 1 study will test whether the experimental drug INV-1120, given alone or with pembrolizumab, is safe and tolerable in adults with advanced solid tumors who have progressed after standard therapies.

  Recruiting Phase 1 Shenzhen Ionova Life Sciences Co., Ltd. · Lafayette, Indiana and 2 other locations · NCT04443088

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.